Page 109 - The Flying Publisher Guide to Hepatitis C Treatment
P. 109
Index | 109
Index
Cobas Taqman HCV Test 33
80/80/80 rule 21 Co-infections 20
Comorbidities 54
AAR 38 Consensus interferon 60
Abbott Real-Time PCR 33 Controlled-release
ABT 072 75 recombinant interferon 63
ABT 267 75 Copegus 101, 104
ABT 333 75 Cyclophilins inhibitors 73
ABT 450 75
ACH-1625 75 DAA 26, 59, 65
Adherence 21, 45, 52 Danoprevir 70, 72, 75
Adverse effects 16, 21 Debio-025 73
African Americans 55 Direct-acting antiviral drugs
Albinterferon 62 26, 59, 65
Alisporivir 73, 75
Allograft 79 Early virological response 25
Anemia 21, 45, 69, 87 EIA 31
APRI 38 End-stage liver disease 19, 79
Autoantibodies 56 EoTR 25
Autoimmune disorders 23 Epoetin 22
Autoimmune hepatitis 56, 87 EVR 25, 46
AZD 7295 75
FibroMeter 39
Bavituximab 75 FibroScan 37
BI201335 69, 72, 75 Fibrosis 13, 14, 35, 48, 80
BI207127 70, 72 Fibrosis Index 38
Biochemical scores 38, 39 FibroTest 39
BMS-650032 72, 75 Filibuvir 75
BMS-790052 72, 73, 75
Boceprevir 14, 68, 107 Genotype 26, 43, 66
Breakthrough 44 Genotype 1 26, 43, 45, 47, 51,
53, 59, 61, 62, 66, 68, 74, 85
Calcineurin inhibitor 81 Genotype 2/3 25, 26, 43, 57
cEVR 25 GS-9190 75
Child-Pugh 40 GS-9256 72, 75
CIFN 60
Cirrhosis 13, 48, 51, 83 HCV 13, 17, 24, 25, 26, 43
